Adverse events: any adverse event, adverse events requiring withdrawal, and serious adverse events · people with diabetic peripheral neuropathy
1 finding from 1 review
Pain at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional impairment and disability Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
General health‐related quality of life · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Serious adverse events · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Fatigue Mental fatigue in moderate‐grade hepatic encephalopathy Wessely and Powell test Scale from 0 to 10 · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of days in hospital (duration of hospitalisation) · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Blood ammonium levels · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Absolute claudication distance (MWD + PWT) (in meters) · intermittent claudication
1 finding from 1 review
Initial claudication distance (PFWD + COT) (in meters) · intermittent claudication
1 finding from 1 review
Quality of life · intermittent claudication
1 finding from 1 review
Progression of disease (to Fontaine stage III or IV, or necessity for intervention (endovascular or surgery)) · intermittent claudication
1 finding from 1 review
Ankle brachial index · intermittent claudication
1 finding from 1 review
Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in ulcer size · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found